Shattuck Labs to Report Fourth-Quarter and Full-Year 2022 Financial Results on February 23, 2023
16 févr. 2023 07h00 HE
|
Shattuck Labs, Inc.
AUSTIN, TX & DURHAM, NC, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional...
Shattuck Labs Announces Participation in Upcoming SVB Securities Global Biopharma Conference
09 févr. 2023 06h01 HE
|
Shattuck Labs, Inc.
AUSTIN, TX & DURHAM, NC, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional...
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2023
09 janv. 2023 07h00 HE
|
Shattuck Labs, Inc.
AUSTIN, TX & DURHAM, NC, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional...
Shattuck Labs Reports Third Quarter 2022 Financial Results and Recent Business Highlights
08 nov. 2022 16h30 HE
|
Shattuck Labs, Inc.
– Completed enrollment in Phase 1 dose-escalation clinical trial of SL-172154 as monotherapy in platinum-resistant ovarian cancer; complete data expected midyear 2023 – – Dosed first patient in...
Shattuck Labs Presents Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
07 nov. 2022 08h00 HE
|
Shattuck Labs, Inc.
- Data from two distinct GADLEN product candidates, one targeting CD20 and another targeting B7-H3, enhanced γδT cell killing of tumor cells, demonstrating preclinical proof-of-concept in the...
Shattuck Labs Announces Participation in Upcoming November Conferences
03 nov. 2022 08h30 HE
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...
Shattuck Labs to Report Third Quarter 2022 Financial Results on November 8, 2022
01 nov. 2022 16h30 HE
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...
Shattuck Labs to Present Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 8-12
05 oct. 2022 16h30 HE
|
Shattuck Labs, Inc.
AUSTIN, TX & DURHAM, NC, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional...
Shattuck Labs Announces Participation in Upcoming September Conferences
01 sept. 2022 16h15 HE
|
Shattuck Labs, Inc.
AUSTIN, TX & DURHAM, NC, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional...
Shattuck Labs Reports Second Quarter 2022 Financial Results and Recent Business Highlights
11 août 2022 07h00 HE
|
Shattuck Labs, Inc.
– Enrollment of Phase 1B clinical trial of SL-172154 in combination with liposomal doxorubicin in platinum-resistant ovarian cancer expected to begin in Q3’2022 with initial combination data expected...